Dr Kathryn McIntosh

Teaching Fellow

Strathclyde Institute of Pharmacy and Biomedical Sciences

Contact

Back to staff profile

Personal statement

I am a research scientist and lecture in Pharmacology and cell signalling here in SIPBS. My research interests lie in the area of GPCRs, focussing on Proteinase activated receptors (PARs). In particular I am interested in the pharmacology of PAR2 and its pathophysiological role in inflammatory disease. Specifically investigating chronic inflammatory disorders such as rheumatoid arthritis and latterly the role of PAR2 in cancer, looking at prostate and breast cancer cell models. I have been working on novel small molecule modulators of PAR2 in collaboration with Dr Craig Jamieson from Pure and Applied Chemistry. Our group consists of 3 PhD students, working in different areas of cell Signalling, as part of the Cellular basis of disease group within SIPBS. I am co-head of the Research committee here in SIPBS and as such regularly sit on the Research and knowledge exchange management meetings. I am also part of the University wide research committee.

Back to staff profile

Publications

TAK1 is an upstream MAP 3 K regulator of a novel non-canonical NFkB pathway stimulated by IL-1b
Farhan Mohammad, McIntosh Kathryn A, Cunningham Margaret R, Plevin Robin, Tinto Kirsty
British Journal of Pharmacology Vol 180, pp. 708-709 (2023)
https://doi.org/10.1111/bph.16110
IL-1β stimulates a novel, IKKα -dependent, NIK -independent activation of non-canonical NFκB signalling
McIntosh Kathryn, Khalaf Yousif H, Craig Rachel, West Christopher, McCulloch Ashley, Waghmare Ajay, Lawson Christopher, Chan Edmond YW, MacKay Simon, Paul Andrew, Plevin Robin
Cellular Signalling Vol 107 (2023)
https://doi.org/10.1016/j.cellsig.2023.110684
The development of proteinase-activated receptor-2 modulators and the challenges involved
McIntosh Kathryn A, Cunningham Margaret R, Bushell Trevor, Plevin Robin
Biochemical Society Transactions Vol 48, pp. 2525-2537 (2020)
https://doi.org/10.1042/BST20200191
Novel protective role for MAP kinase phosphatase 2 in inflammatory arthritis
Schroeder Juliane, Ross Kirsty, McIntosh Kathryn, Jabbar Shilan Khayrula Jabbar, Woods Stuart, Crowe Jenny, Patterson-Kane Janet C, Alexander James, Lawrence Catherine, Plevin Robin
RMD Open Vol 5, pp. e000711 (2019)
https://doi.org/10.1136/rmdopen-2018-000711
Inhibition of cytokine-mediated JNK signalling by purinergic P2Y11 receptors, a novel protective mechanism in endothelial cells
Ng Pei Y, McIntosh Kathryn A, Hargrave Gillian, Ho Ka H, Paul Andrew, Plevin Robin
Cellular Signalling Vol 51, pp. 59-71 (2018)
https://doi.org/10.1016/j.cellsig.2018.07.016
Inhibitory Kappa B kinase α (IKKα) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers
Anthony Nahoum G, Baiget Jessica, Berretta Giacomo, Boyd Marie, Breen David, Edwards Joanne, Gamble Carly, Gray Alexander I, Harvey Alan L, Hatziieremia Sophia, Ho Ka Ho, Huggan Judith K, Lang Stuart, Llona-Minguez Sabin, Luo Jia Lin, McIntosh Kathryn, Paul Andrew, Plevin Robin J, Robertson Murray N, Scott Rebecca, Suckling Colin J, Sutcliffe Oliver Brook, Young Louise C, MacKay Simon P
Journal of Medicinal Chemistry Vol 60, pp. 7043-7066 (2017)
https://doi.org/10.1021/acs.jmedchem.7b00484

More publications

Back to staff profile

Research Interests

Current Collaborators: 

CXCL12-IKKa project = Professor Valerie Speirs (University of Aberdeen) and Dr Craig Jamieson (UoS)

PAR2-Osteoarthrits project = Professor Robin Plevin (UoS), Dr Anne Crilly (University of the West of Scotland), Dr Craig Jamieson (UoS) and Dr Zahra Rattray (UoS)

 

Professional Activities

Interleukin-1b stimulates a novel early activation of non-canonical NF Kappa B signalling pathway linked to CXCL12 production
Speaker
13/9/2022

More professional activities

Projects

Developing novel inhibitors to prevent the induction of CXCL12 in breast cancer fibroblasts cells
McIntosh, Kathryn (Principal Investigator)
CXCL12 plays an important role in a number of diseases. In cancer it has a key role in sustaining the tumour microenvironment and is implicated in ovarian and breast cancers. One strategy is to develop new drugs that block the formation of CXCL12 prior to the activation of its receptor CXCR4. A screen conducted through SULSA-Biocity has lead to 50 propriety compounds to be taken forward for testing.
28-Jan-2022 - 29-Jan-2026
Development and preclinical validation of novel PAR2 inhibitors for the treatment of Osteoarthritis
McIntosh, Kathryn (Principal Investigator) Crilly, Anne (Co-investigator) Jamieson, Craig (Co-investigator) Plevin, Robin (Co-investigator) Rattray, Zahra (Co-investigator)
01-Jan-2020 - 30-Jan-2022
Preventing the damaging effects of cancer chemotherapy and radiation treatment on human endothelial cells targeting the JNK pathway
Plevin, Robin (Principal Investigator) Boyd, Marie (Co-investigator) McIntosh, Kathryn (Co-investigator)
Preventing the damaging effects of cancer chemotherapy and radiation treatment on human endothelial cells targeting the JNK pathway
01-Jan-2019 - 31-Jan-2023
Inhibition of human CXCL12 expression by novel inhibitory kappa B kinase alpha compounds - a novel approach for new drug development in breast cancer
McIntosh, Kathryn (Principal Investigator) Patton, Chloe (Post Grad Student)
08-Jan-2018 - 31-Jan-2021
Investigating the role of the non-canconical arm of the NFkB pathway in pancreatic cancer, utilising novel inhibitory compounds.
McIntosh, Kathryn (Principal Investigator)
The NFkB pathway is an important transcription factor pathway involved in the regulation of a large number of cellular processes. While the canonical arm of this pathway has been studied extensively the non-canonical arm has been largely overlooked. Is has however been implicated in cell growth, proliferation and survival in cancer, therefore inhibiting components of this pathway is an attractive therapeutic approach to regulating cancer disease progression [3]. We have synthesised selective inhibitors of the kinases IKKa, and NIK which require further pharmacological characterisation, and their use will develop our understanding of the role of these kinases in cancer.
01-Jan-2018 - 02-Jan-2019
Development of novel PAR2 antagonists to treat inflammatory disease
McIntosh, Kathryn (Principal Investigator)
Based on the recently published PAR2 crystal structure, a novel series of PAR2 antagonists were developed - namely the AZ series. However these require further target validation and elucidation of there pharmacological properties, and from these novel derivatives will be developed.
05-Jan-2018 - 29-Jan-2025

More projects

Back to staff profile

Contact

Dr Kathryn McIntosh
Teaching Fellow
Strathclyde Institute of Pharmacy and Biomedical Sciences

Email: kathryn.a.mcintosh@strath.ac.uk
Tel: 548 2909